A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 185, Issue 9, 2002, Pages 1251-1260

  Opravil, Milos ^a   Hirschel, Bernard ^b   Lazzarin, Adriano ^g   Furrer, Hansjakob ^c   Chave, Jean Philippe ^d   Yerly, Sabine ^b   Bisset, Leslie R ^a   Fischer, Marek ^a   Vernazza, Pietro ^e   Bernasconi, Enos ^e   Battegay, Manuel ^f   Ledergerber, Bruno ^a   Günthard, Huldrych ^a   Howe, Colin ^h   Amiet, R ⁱ   Battegay, M ⁱ   Bernasconi, E ⁱ   Bucher, H ⁱ   Burgisser P ⁱ   Egger, M ⁱ   Erb, P ⁱ   Fierz, W ⁱ   Flepp, M ⁱ   Francioli, P ⁱ   Furrer, H J ⁱ   Gorgievski, M ⁱ   Gunthard H ⁱ   Grob, P ⁱ   Hirschel, B ⁱ   Kind, C ⁱ   Klimkait, T ⁱ   Ledergerber, B ⁱ   Lauper, U ⁱ   Opravil, M ⁱ   Paccaud, F ⁱ   Pantaleo, G ⁱ   Perrin, L ⁱ   Pichler, W ⁱ   Piffaretti, J C ⁱ   Rickenbach, M ⁱ   Rudin, C ⁱ   Sudre, P ⁱ   Schiffer, V ⁱ   Schupbach, J ⁱ   Telenti, A ⁱ   Vernazza, P ⁱ   Weber, R ⁱ   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Department of Medicine   (Switzerland)

^e Cantonal Hospital Group   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HUMANS; LAMIVUDINE; LIPIDS; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 0036569234     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/340312     Document Type: Article

References (39)

1. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
2. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens
3. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy
4. A randomized trial of three maintenance regim̂ens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
5. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study
6. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
7. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
8. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
9. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
10. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens
11. Transmission of antiretroviral-drug-resistant HIV-1 variants
12. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection
13. + T-cell determinations in persons infected with human immunodeficiency virus (HIV)
14. Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues
15. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy
16. PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells
17. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
18. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
19. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretrovirat-naive HIV-infected adults: A randomized equivalence trial
20. + T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency
21. + lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy
22. + T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study
23. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults
24. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
25. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue
26. Lymphoid tissue viral burden and duration of viral suppression in plasma
27. Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor-sparing highly active antiretroviral therapy
28. Cell-associated HIV-1 RNA in blood as indicator of viral load in lymph nodes
29. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
30. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: A randomized trial of double versus triple therapy. Swiss HIV Cohort Study
31. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years
32. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir
33. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study
34. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
35. Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA levels - Results of a prospective, randomized, multicenter, open-label study (DMP266-049)
36. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks
37. Mechanism of virological failure after substitution of a protease inhibitor by nevirapine in patients with controlled HIV-1 RNA
38. Substitution of a nonnucleoside reverse-transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA
39. An open randomized study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy